148 related articles for article (PubMed ID: 18380793)
1. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y
Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643
[TBL] [Abstract][Full Text] [Related]
3. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
Kaida Y; Inui N; Suda T; Nakamura H; Watanabe H; Chida K
Clin Pharmacol Ther; 2008 Apr; 83(4):589-94. PubMed ID: 18212800
[TBL] [Abstract][Full Text] [Related]
4. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.
Comets E; Ikeda K; Hoff P; Fumoleau P; Wanders J; Tanigawara Y
J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):257-83. PubMed ID: 14650374
[TBL] [Abstract][Full Text] [Related]
10. The unanswered question: what is the determinant of S-1 pharmacokinetics?
Ichikawa W; Fujita K; Sasaki Y
Clin Pharmacol Ther; 2008 Aug; 84(2):203; author reply 204. PubMed ID: 18388865
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
Yasui H; Kawakami T; Kashiwagi H; Mori K; Omae K; Kasai J; Yoshisue K; Kawahira M; Tsushima T; Machida N; Fukutomi A; Yamaguchi K
Int J Clin Oncol; 2019 Jun; 24(6):660-665. PubMed ID: 31011915
[TBL] [Abstract][Full Text] [Related]
12. Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Ishii Y; Suzuki S; Takahashi Y; Takayama T; Asai S
Cancer Chemother Pharmacol; 2010 Jul; 66(2):333-43. PubMed ID: 19921195
[TBL] [Abstract][Full Text] [Related]
13. Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
Fujita K; Ichikawa W; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Sasaki Y
Ann Oncol; 2009 May; 20(5):946-9. PubMed ID: 19150953
[TBL] [Abstract][Full Text] [Related]
14. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
[TBL] [Abstract][Full Text] [Related]
15. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.
Wang H; Bian T; Liu D; Jin T; Chen Y; Lin A; Chen C
Pharmacogenomics; 2011 Apr; 12(4):481-92. PubMed ID: 21521021
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
17. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
18. Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Lim HS; Ryu KW; Lee JH; Kim YW; Ju Choi I; Kim MJ; Park YI; Hwang A; Park SR
J Clin Pharmacol; 2015 Aug; 55(8):926-35. PubMed ID: 25810324
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Fujita K; Nakayama H; Ichikawa W; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Sunakawa Y; Yamashita K; Mizuno K; Ishida H; Araki K; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Hirose T; Sasaki Y
Drug Metab Dispos; 2009 Jul; 37(7):1375-7. PubMed ID: 19389859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]